Transpire Bio, a development-stage pharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, has today announced a definitive agreement with INTO (Inhalation Together) to develop TRB-5, TRB-6 and TRB-7, inhaled medicines for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD). INTO is an alliance in the field of inhalation product development to provide formulation services for respiratory products.
INTO is a partnership in the field of dry powder inhalation by DFE Pharma (excipient solutions provider), Harro Höfliger (equipment supplier), and Sterling (API manufacturer) to provide formulation services for respiratory products.
TRB-5, TRB-6 and TRB-7, marking the expansion of Transpire Bio into different device and formulation technologies, are inhaled products being developed for the US and European markets. With a focus on complex device, formulation and manufacturing process, these three new products will establish Transpire Bio as a capable drug developer in the inhalation space, bringing new, complex inhaled medicines to market.
“We have been carefully planning to expand our technical capabilities in order to improve access to a broader portfolio of life-saving inhaled therapies, which will also help us better address areas of significant unmet medical needs,” said Dr. Xian-Ming Zeng, CEO of Transpire Bio. “With TRB-5, TRB-6, and TRB-7 we are tackling the complexities of inhaled drug development by harnessing the capabilities of long-trusted partners. We are very excited to be working with INTO and their associated companies to advance these important medicines.”
Thomas Weller, CEO of Harro Höfliger, representing INTO added: “We are very pleased to be selected as a partner by Transpire Bio and we look forward to leveraging our collective experience and products in support of their broad access to complex medicines and solutions to unmet needs ”
According to statistics from the World Health Organization, asthma affected approximately 262 million people in 2019, and accounted for approximately 455,000 deaths. COPD was the third-leading cause of death in 2019, with approximately 3.2 million lives lost.
Learn more about INTO: www.intoinhalation.com